Hyperion Logo
Hyperion Therapeutics to Present at 27th Annual ROTH Conference
March 06, 2015 09:00 ET | Hyperion Therapeutics, Inc.
BRISBANE, Calif., March 6, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the 27th Annual ROTH Conference at 12:30 p.m....
Hyperion Logo
Hyperion Therapeutics Observes Rare Disease Day 2015
February 27, 2015 08:00 ET | Hyperion Therapeutics, Inc.
BRISBANE, Calif., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today joins with patients and their families, caregivers, researchers, the biopharmaceutical industry and...
Hyperion Logo
Hyperion Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results
February 26, 2015 16:05 ET | Hyperion Therapeutics, Inc.
UCD Product Portfolio Generates $113.6 Million for Fiscal Year 2014 and $30.8 Million in Net Sales During the Fourth Quarter of 2014 -- Company Generates $31 Million in Operating Cash Flows in...
Hyperion Logo
Hyperion Therapeutics to Present at the Cowen and Company 35th Annual Health Care Conference
February 25, 2015 16:45 ET | Hyperion Therapeutics, Inc.
BRISBANE, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the Cowen and Company 35th Annual Health Care...
Hyperion Logo
Hyperion Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results After Market on February 26, 2015
February 19, 2015 16:00 ET | Hyperion Therapeutics, Inc.
BRISBANE, Calif., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report fourth quarter and full year 2014 financial results after market...
Hyperion Logo
Hyperion Therapeutics Enters Into Completion of Phase III Clinical Trial, Option and Mutual Release Agreement With Clal Biotechnology Industries and Yeda Research and Development Company
February 17, 2015 01:00 ET | Hyperion Therapeutics, Inc.
BRISBANE, Calif., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) ("Hyperion") today announced that it has amicably resolved its disputes, and entered into a completion of...
Hyperion Logo
Hyperion Therapeutics Initiates Clinical Study to Further Evaluate RAVICTI(R) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders
February 10, 2015 09:00 ET | Hyperion Therapeutics, Inc.
BRISBANE, Calif., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the dosing of the first patient in its HPN-100-009 study in pediatric subjects under two...
Hyperion Logo
Hyperion Therapeutics to Present at the 2015 Leerink Global Healthcare Conference
February 04, 2015 16:00 ET | Hyperion Therapeutics, Inc.
BRISBANE, Calif., Feb. 4, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the 2015 Leerink Global Healthcare Conference...
Hyperion Logo
Hyperion Therapeutics Announces Data Published in Genetics in Medicine Showing Blood Ammonia and Glutamine as Predictors of Hyperammonemic Crises in Patients With Urea Cycle Disorders
January 12, 2015 09:25 ET | Hyperion Therapeutics, Inc.
BRISBANE, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the online publication in Genetics in Medicine of analyses from four short-term switchover...
Hyperion Logo
Hyperion Therapeutics Added to Nasdaq Biotechnology Index (NBI)
December 18, 2014 16:05 ET | Hyperion Therapeutics, Inc.
BRISBANE, Calif., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index®...